Table 1.
Baseline characteristics and details of PRN ranibizumab injections overall, and for group 1 and 2 eyes, and eyes with and without PCV
| Characteristics and injection intervals* | Total eyes (N=202) | Group 1† (N=149) | Group 2‡ (N=53) | Eyes with PCV (N=34) | Eyes without PCV (N=168) |
|---|---|---|---|---|---|
| Male patients | 67 (33.2) | 48 (32.2) | 19 (35.8) | 10 (29.4) | 55 (32.7) |
| Female patients | 135 (66.8) | 101 (67.8) | 34 (64.2) | 24 (70.6) | 113 (67.3) |
| Mean age (years) | 77.9±6.4 (60–91) | 78.1±6.5 (60–91) | 77.4±6.2 (65–91) | 76.2±7.0 (62–87) | 78.2±6.3 (60–91) |
| Interval between injections 1 and 6 (months) | 10.4±4.6 (5–30) | 8.3±1.7 (5–11) | 16.4±4.9 (12–30) | 8.8±2.3 (6–16) | 10.8±4.8§ (6–28) |
| Interval between injections 1 and 8 (months) | 15.4±5.7 (5–28) | 12.9±3.0 (8–21) | 22.4±5.6 (15–34) | 13.8±3.9 (8–22) | 15.7±5.9 (8–34)¶ |
*Data are presented as n (%) or mean±SD (range).
†<12 months between injections 1 and 6.
‡≥12 months between injections 1 and 6.
§p=0.02 versus eyes with PCV.
¶p=0.08 versus eyes with PCV.
PCV, polypoidal choroidal vasculopathy; PRN, pro re nata (as needed).